[1] |
MaeDermot KD, Holmes A, Miners AH. Anderson-Fabry disease:clinical manifestations and impact of disease in a cohort of 98 hemizygous males [J]. J Med Genet, 2001, 38(11): 750-760.
|
[2] |
Faggiano A, Pisani A, Milone F, et al. Endocrine dysfunction in patients with Fabry disease[J].Clin Endocrinol Metab, 2006, 91(11): 4319-4325.
|
[3] |
Shi Q, Chen J, Pongmoragot J, et al. Prevalence of Fabry disease in stroke patients-a systematic review and meta-analysis [J]. J Stroke Cerebrovasc Dis,2014, 23(5): 985-992.
|
[4] |
Tojo K, Oota M, Honda H, et al. Possible thyroidal involvement in a case of Fabry disease [J]. Intern Med, 1994, 33(3): 172-176.
|
[5] |
Katsumata N, Ishiguro A, Watanabe H. Fabry disease superimposed on overt autoimmune hypothyroidism[J]. Clin Pediatr Endocrinol, 2011, 20(4): 95-98.
|
[6] |
Mehta A, Ricci R, Widmer U, et al.Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey [J]. Eur J Clin Invest, 2004, 34(3): 236-242.
|
[7] |
Fletcher J, Wilcox WR, Waldek S, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry [J].J Inherit Metab Dis,2007,30(2): 184-192.
|
[8] |
潘晓霞,欧阳彦,陈楠等.法布里病83例临床病理特点分析[J].中国实用内科杂志,2014,34(3): 262-266.
|
[9] |
Quinta R, Rodrigues D, Assunção M, et al. Reduced glycosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy [J]. Gene, 2014, 536(1): 97-104.
|
[10] |
Faggiano A, Severino R, Ramundo V, et al. Thyroid function in Fabry disease before and after enzyme replacement therapy [J].Minerva Endocrinol, 2011, 36(1): 1-5.
|